Literature DB >> 2450158

Antibodies as antigens. The use of mouse monoclonal antibodies to focus human T cells against selected targets.

A Lanzavecchia1, S Abrignani, D Scheidegger, R Obrist, B Dörken, G Moldenhauer.   

Abstract

We found that three tumor patients treated with mouse mAbs have T cells that recognize processed mouse Ig on autologous APC in a class II-restricted fashion, and we have shown that mouse mAbs directed against various cell surface molecules can be used as antigens to focus these T cells on an MHC class II-positive target of choice.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2450158      PMCID： PMC2188824          DOI： 10.1084/jem.167.2.345

Source DB:  PubMed          Journal:  J Exp Med        ISSN： 0022-1007            Impact factor:   14.307


  15 in total

1.  Growth inhibition of a B cell leukemia: evidence implicating an anti-idiotype immune response for protective tumor immunity.

Authors:  R P Ciavarra; E S Vitetta; J Forman
Journal:  J Immunol       Date:  1986-08-15       Impact factor: 5.422

2.  Antigen-specific interaction between T and B cells.

Authors:  A Lanzavecchia
Journal:  Nature       Date:  1985 Apr 11-17       Impact factor: 49.962

Review 3.  Immunotoxins.

Authors:  E S Vitetta; J W Uhr
Journal:  Annu Rev Immunol       Date:  1985       Impact factor: 28.527

4.  Studies with B-cell allo- and hetero-antisera: parallel reactivity and special properties.

Authors:  R J Winchester; C Y Wang; J Halper; T Hoffman
Journal:  Scand J Immunol       Date:  1976       Impact factor: 3.487

5.  Acquisition of specific cytotoxic activity by human T4+ T lymphocytes in culture.

Authors:  B Fleischer
Journal:  Nature       Date:  1984 Mar 22-28       Impact factor: 49.962

6.  Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.

Authors:  S L Morrison; M J Johnson; L A Herzenberg; V T Oi
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

7.  Is the T-cell receptor involved in T-cell killing?

Authors:  A Lanzavecchia
Journal:  Nature       Date:  1986 Feb 27-Mar 5       Impact factor: 49.962

Review 8.  Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma.

Authors:  J Ritz; S F Schlossman
Journal:  Blood       Date:  1982-01       Impact factor: 22.113

9.  Tolerance to rat monoclonal antibodies. Implications for serotherapy.

Authors:  R J Benjamin; S P Cobbold; M R Clark; H Waldmann
Journal:  J Exp Med       Date:  1986-06-01       Impact factor: 14.307

10.  Helper activity is required for the in vivo generation of cytotoxic T lymphocytes.

Authors:  J A Keene; J Forman
Journal:  J Exp Med       Date:  1982-03-01       Impact factor: 14.307
View more
  27 in total

1.  A novel strategy for targeting CD4+ PPD-reactive T cells against tumour cells using PPD monoclonal antibody heteroconjugates.

Authors:  A M Montgomery; M G Wing; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

Review 2.  Biological response modifiers in the management of patients with breast cancer.

Authors:  D L Longo; L C Hartmann
Journal:  Breast Cancer Res Treat       Date:  1990-09       Impact factor: 4.872

3.  Improving the chance of cure of follicular lymphoma by combining immunotherapy and radioimmunotherapy based on anti-CD20 antibodies?

Authors:  F Buchegger; J-P Mach; O W Press; A Bischof Delaloye; S M Larson; J O Prior; N Ketterer
Journal:  Ann Oncol       Date:  2013-05-23       Impact factor: 32.976

Review 4.  Monoclonal antibodies in cancer therapy.

Authors:  R Gruber; E Holz; G Riethmüller
Journal:  Springer Semin Immunopathol       Date:  1996

Review 5.  Biology of monoclonal antibodies in tumor therapy.

Authors:  C H Janson
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

6.  Immune responses in advanced colorectal cancer following repeated intradermal vaccination with the anti-CEA murine monoclonal antibody, PR1A3: results of a phase I study.

Authors:  A P Zbar; H Thomas; R W Wilkinson; M Wadhwa; K N Syrigos; E L Ross; P Dilger; T G Allen-Mersh; W A Kmiot; A A Epenetos; D Snary; W F Bodmer
Journal:  Int J Colorectal Dis       Date:  2005-04-30       Impact factor: 2.571

7.  The role of humoral and cellular immunity in patients developing human anti-murine immunoglobulin antibody responses after radioimmunotherapy.

Authors:  C Kosmas; S Man; A A Epenetos; N S Courtenay-Luck
Journal:  Br J Cancer Suppl       Date:  1990-07

8.  An anti-CD19 antibody coupled to a tetanus toxin peptide induces efficient Fas ligand (FasL)-mediated cytotoxicity of a transformed human B cell line by specific CD4+ T cells.

Authors:  G Eberl; S Jiang; Z Yu; P Schneider; G Corradin; J P Mach
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

9.  Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). I. May induction of ab1-reactive T cells and anti-anti-idiotypic antibodies (ab3) lead to tumor regression after mAb therapy?

Authors:  J Fagerberg; J E Frödin; H Wigzell; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

10.  Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). II. Is induction of anti-idiotype reactive T cells (T3) of importance for tumor response to mAb therapy?

Authors:  J Fagerberg; J E Frödin; P Ragnhammar; M Steinitz; H Wigzell; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1994-03       Impact factor: 6.968
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.